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Abstract
Background: SAMHD1 mediates resistance to anti-cancer nucleoside analogues, including cytarabine, decitabine,
and nelarabine that are commonly used for the treatment of leukaemia, through cleavage of their
triphosphorylated forms. Hence, SAMHD1 inhibitors are promising candidates for the sensitisation of leukaemia cells
to nucleoside analogue-based therapy. Here, we investigated the effects of the cytosine analogue CNDAC, which
has been proposed to be a SAMHD1 inhibitor, in the context of SAMHD1.
Methods: CNDAC was tested in 13 acute myeloid leukaemia (AML) cell lines, in 26 acute lymphoblastic leukaemia
(ALL) cell lines, ten AML sublines adapted to various antileukaemic drugs, 24 single cell-derived clonal AML sublines,
and primary leukaemic blasts from 24 AML patients. Moreover, 24 CNDAC-resistant sublines of the AML cell lines
HL-60 and PL-21 were established. The SAMHD1 gene was disrupted using CRISPR/Cas9 and SAMHD1 depleted
using RNAi, and the viral Vpx protein. Forced DCK expression was achieved by lentiviral transduction. SAMHD1
promoter methylation was determined by PCR after treatment of genomic DNA with the methylation-sensitive
HpaII endonuclease. Nucleoside (analogue) triphosphate levels were determined by LC-MS/MS. CNDAC interaction
with SAMHD1 was analysed by an enzymatic assay and by crystallisation.
Results: Although the cytosine analogue CNDAC was anticipated to inhibit SAMHD1, SAMHD1 mediated intrinsic
CNDAC resistance in leukaemia cells. Accordingly, SAMHD1 depletion increased CNDAC triphosphate (CNDAC-TP)
levels and CNDAC toxicity. Enzymatic assays and crystallisation studies confirmed CNDAC-TP to be a SAMHD1
substrate. In 24 CNDAC-adapted acute myeloid leukaemia (AML) sublines, resistance was driven by DCK (catalyses
initial nucleoside phosphorylation) loss. CNDAC-adapted sublines displayed cross-resistance only to other DCK
substrates (e.g. cytarabine, decitabine). Cell lines adapted to drugs not affected by DCK or SAMHD1 remained CNDA
C sensitive. In cytarabine-adapted AML cells, increased SAMHD1 and reduced DCK levels contributed to cytarabine
and CNDAC resistance.
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Conclusion: Intrinsic and acquired resistance to CNDAC and related nucleoside analogues are driven by different
mechanisms. The lack of cross-resistance between SAMHD1/ DCK substrates and non-substrates provides scope for
next-line therapies after treatment failure.
Keywords: Leukemia, Acute myeloid leukemia, Acute lymphoblastic leukemia, CNDAC, Sapacitabine, SAMHD1, DCK,
Intrinsic resistance, Acquired resistance
Background
Drug resistance is a main obstacle in the successful treat-
ment of cancer [4, 9, 31]. Resistance can be either intrinsic
or acquired. Intrinsic resistance means that a therapy-
naïve cancer does not respond to treatment right from the
start. In acquired resistance, there is an initial therapy re-
sponse, but resistance develops over time [31, 40].
Intrinsic and acquired resistance are conceptually differ-
ent. Intrinsic resistance is a collateral event during carcino-
genesis not influenced by treatment. In contrast, acquired
resistance is the consequence of a directed evolution driven
by therapy. In agreement, discrepancies have been detected
between drug resistance mechanisms in the intrinsic and
the acquired resistance setting [31, 36, 40, 44].
Sterile alpha motif and histidine-aspartate domain-
containing protein 1 (SAMHD1) is a deoxynucleoside
triphosphate (dNTP) triphosphohydrolase that cleaves
physiological dNTPs into deoxyribonucleotides and inor-
ganic triphosphate [11, 38]. SAMHD1 also inactivates
the triphosphorylated forms of some anti-cancer nucleo-
side analogues [13, 21, 36, 39, 41, 50]. High SAMHD1
levels indicate poor clinical response to nucleoside ana-
logues such as cytarabine, decitabine, and nelarabine in
acute myeloid leukaemia (AML), acute lymphoblastic
leukaemia, and Hodgkin lymphoma [36, 39, 41, 50].
Moreover, previous findings indicated differing roles of
SAMHD1 in intrinsic and acquired resistance to nucleo-
side analogues [36, 41].
Here, we investigated intrinsic and acquired resistance
against the nucleoside analogue 2′-C-cyano-2′-deoxy-1-β-D-
arabino-pentofuranosyl-cytosine (CNDAC). CNDAC and its
orally available prodrug sapacitabine display clinical activity
against AML [6, 18–20]. We selected CNDAC, because, in
contrast to SAMHD1 substrates such as cytarabine and deci-
tabine, it has been proposed to be a SAMHD1 inhibitor [14].
CNDAC is further interesting due to its unique mechanism
of action among deoxycytidine analogues, which is charac-
terised by CNDAC triphosphate (CNDAC-TP) incorpor-
ation into DNA initially causing single strand breaks and G2
cell cycle arrest [1, 2, 12, 24–27].
Methods
Compounds
CNDAC was purchased from biorbyt (via Biozol, Eching,
Germany), 5-azacytidine, cytarabine, cladribine,
clofarabine, decitabine, and fludarabine from Tocris Bio-
sciences (via Bio-Techne GmbH, Wiesbaden, Germany),
6-thioguanine, ganetespib, molibresib, olaparib, sapacita-
bine, venetoclax, and vismodegib from MedChemEx-
press (via Hycultec, Beutelsbach, Germany),
daunorubicin, gedatolisib, and volasertib from Selleck-
chem (Berlin, Germany), gemcitabine from Hexal (Holz-
kirchen, Germany), GTP and dATP from Thermo
Scientific (Dreieich, Germany), and CNDAC-TP from
Jena Bioscience GmbH (Jena, Germany).
Cell culture
The human AML cell lines HEL (DSMZ No. ACC 11),
HL-60 (DSMZ No. ACC 3), KG-1 (DSMZ No. ACC 14),
ML-2 (DSMZ No. ACC 15), MOLM-13 (DSMZ No.
ACC 554), MONO-MAC-6 (DSMZ No. ACC 124),
MV4–11 (DSMZ No. ACC 102), NB-4 (DSMZ No. ACC
207), OCI-AML-2 (DSMZ No. ACC 99), OCI-AML-3
(DSMZ No. ACC 582), PL-21 (DSMZ No. ACC 536),
SIG-M5 (DSMZ No. ACC 468), and THP-1 (DSMZ No.
ACC16) and the human ALL cell lines 697 (DSMZ No.
ACC 42), ALL-SIL (DSMZ No. ACC 511), BALL-1
(DSMZ No. ACC 742), CTV-1 (DSMZ No. ACC 40),
GRANTA-452 (DSMZ No. ACC 713), HAL-01 (DSMZ
No. ACC 610), HSB-2 (DSMZ No. ACC 435), JURKAT
(DSMZ No. ACC 282), KE-37 (DSMZ No. ACC 46),
MHH-CALL-4 (DSMZ No. ACC 337), MN-60 (DSMZ
No. ACC 138), MOLT-4 (DSMZ No. ACC 362),
MOLT-16 (DSMZ No. ACC 29), NALM-6 (DSMZ No.
ACC 128), NALM-16 (DSMZ No. ACC 680), P12-
ICHIKAWA (DSMZ No. ACC 34), REH (DSMZ No.
ACC 22), ROS-50 (DSMZ No. ACC 557), RPMI-8402
(DSMZ No. ACC 290), RS4;11 (DSMZ No. ACC 508),
SEM (DSMZ No. ACC 546), TANOUE (DSMZ No.
ACC 399), and TOM-1 (DSMZ No. ACC 578) were ob-
tained from DSMZ (Deutsche Sammlung von Mikroor-
ganismen und Zellkulturen GmbH, Braunschweig,
Germany). The ALL cell line CCRF-CEM (ATCC No.
CCL-119) was received from ATCC (Manassas, VA, US),
the ALL cell line KARPAS231 from Cambridge Enter-
prise Ltd. (Cambridge, UK), and the ALL cell line J-
JHAN was kindly provided by Professor R. Tedder (Uni-
versity College London) [5].
Drug-resistant cell sublines were established by con-
tinuous exposure of sensitive parental cell lines HL-60
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and PL-21 to step-wise increasing drug concentrations,
as previously described [30] and are part of the Resistant
Cancer Cell Line (RCCL) collection (https://www.kent.
ac.uk/stms/cmp/RCCL/RCCLabout.html) [31]. Briefly,
cells were cultured at increasing drug concentrations,
starting with concentrations that inhibited the viability
of the parental cell lines by 50% (IC50). Drug concentra-
tions were increased every 2 to 6 weeks until cells readily
grew in the presence of the drug. In this way 12 inde-
pendent CNDAC-resistant sublines of HL-60 and PL-21
were generated each and designated as HL-60rCNDA
C200nMI– XII and PL-21rCNDAC2μMI-XII. HL-60 cells
with acquired resistance to the drugs cytarabine (Ara-C),
arabinosylguanine (Ara-G), 5-azacytidine (AZA), fludara-
bine (FLUDA), 6-mercaptopurine (6-MP), venetoclax
(VENE), olaparib (OLA), and volasertib (VOLA) were
designated as HL-60rAra-C2μg/ml, HL-60rAra-G100μM,
HL-60rAZA1µM, HL-60rFLUDA1μg/ml, HL-60r6-MP2μM,
HL-60rVENE2μM, HL-60rOLA20μM and HL-
60rVOLA200nM.
Clonal sublines were generated by limiting dilution.
Cells were plated at a density of 1 cell per well on a 96-
well plate and grown for 1–2 weeks. Wells with only one
visible cell colony were identified and the respective
clones were expanded.
SAMHD1-deficient THP-1 (THP-1 KO) cells and con-
trol cells (THP-1 CTRL) were generated using CRISPR/
Cas9 approach as previously described [36, 41, 47].
THP-1 cells were plated at a density of 2 × 105 cells/ mL.
After 24 h, 2.5 × 106 cells were suspended in 250 μl Opti-
MEM, mixed with 5 μg CRISPR/Cas plasmid DNA, and
electroporated in a 4-mm cuvette using an exponential
pulse at 250 V and 950 mF in a Gene Pulser electropor-
ation device (Bio-Rad Laboratories, Feldkirchen,
Germany). We used a plasmid encoding a CMV-
mCherry-Cas9 expression cassette and a human
SAMHD1 gene specific gRNA driven by the U6 pro-
moter. An early coding exon of the SAMHD1 gene was
targeted using the following gRNA construct: 5′-
CGGAAGGGGTGTTTGAGGGG-3′. Cells were
allowed to recover for 2 days in 6-well plates filled with
4 ml medium per well before being FACS sorted for
mCherry-expression on a BD FACS Aria III (BD Biosci-
ences, Heidelberg, Germany). For subsequent limiting
dilution cloning, cells were plated at a density of 5, 10,
or 20 cells per well of nine round-bottom 96-well plates
and grown for 2 weeks. Plates were scanned for absorp-
tion at 600 nm and growing clones were identified using
custom software and picked and duplicated by a Biomek
FXp (Beckman Coulter, Krefeld, Germany) liquid hand-
ling system.
DCK-expressing MV4–11rAra-C2μg/ml and MOLM-
13rAra-C2μg/ml cells were established by lentiviral trans-
duction and designated as MV4–11rAra-C2μg/ml-pWPI+
DCK and MOLM-13rAra-C2μg/ml-pWPI+DCK (or
MV4–11rAra-C2μg/ml-pWPI and MOLM-13rAra-
C2μg/ml-pWPI for control cells transduced with the
empty vector). To generate the pWPI+DCK plasmid, the
dCK gene was PCR-amplified from pDNR-Dual_dCK
(DNAsu HsCD00000962) using Pfu DNA polymerase
(Promega, Germany) and gene-specific primers (Eurofins
Genomics, Germany) and subcloned into pWPI IRES
puro via BamHI/SpeI. The plasmid was verified by
Sanger sequencing (Eurofins Genomics, Germany). For
the generation of lentiviral vectors 293 T cells were co-
transfected with pWPI+DCK (or pWPI as control),
Addgene packaging plasmid pPAX, an envelope plasmid
encoding VSV-G and pAdVAntage (Promega). Four days
after transfection, lentiviral vectors were harvested and
concentrated by ultracentrifugation. For lentiviral trans-
duction MV4–11rAra-C2μg/ml and MOLM-13rAra-
C2μg/ml cells were seeded at 5 × 105 cells/ well of a 96-
well-plate and spinoculated with the lentiviral vectors.
24 h after transduction, successfully transduced cells
were selected with 3 μg/ml puromycin (Sigma-Aldrich)
and DCK expression was monitored by Western Blot.
All cell lines were cultured in IMDM (Biochrom, Cam-
bridge, UK) supplemented with 10% FBS (SIG-M5 20%
FBS, Sigma-Aldrich, Taufkirchen, Germany), 4 mM L-
Glutamine (Sigma-Aldrich), 100 IU/ml penicillin (Sigma-
Aldrich), and 100 mg/ml streptomycin (Sigma-Aldrich)
at 37 °C in a humidified 5% CO2 incubator. Cell lines
were routinely tested for Mycoplasma, using the MycoA-
lert PLUS assay kit from Lonza (Basel, Switzerland), and
were authenticated by short tandem repeat profiling.
Primary AML samples
Peripheral blood or bone marrow samples derived from
AML patients between 2018 and 2020 were obtained
from the UCT Biobank of the University Hospital Frank-
furt. The use of peripheral blood and bone marrow aspi-
rates was approved by the Ethics Committee of
Frankfurt University Hospital (approval no. SHN-03-
2017). All patients gave informed consent to the collec-
tion of samples and to the scientific analysis of their data
and of biomaterial obtained for diagnostic purposes ac-
cording to the Declaration of Helsinki.
Mononuclear cell (MNC) fractions were purified by
gradient centrifugation with Biocoll cell separation solu-
tion (Merck Millipore, Darmstadt, Germany). Leukemic
cells were enriched by negative selection with a combin-
ation of CD3-, CD19- and CD235a-microbeads (all ob-
tained from Miltenyi Biotec, Bergisch Gladbach,
Germany, 130–050-301, 130–050-101, 130–050-501) ac-
cording to the manufacturer’s instructions and separated
by the autoMACS™ Pro Separator (Miltenyi Biotec).
FACS staining and treatment for viability assays of AML
blasts was executed immediately after isolation. Culture
Rothenburger et al. Journal of Experimental & Clinical Cancer Research          (2021) 40:317 Page 3 of 19
medium for AML blasts consisted of IMDM (Biochrom)
supplemented with 10% FBS, 4 mML-glutamine, 25 ng/
ml hTPO, 50 ng/ml hSCF, 50 ng/ml hFlt3-Ligand and
20 ng/ml hIL-3 (all obtained from Miltenyi Biotec, 130–
094-013, 130–096-695, 130–096-479, 130–095-069).
Viability assay
The viability of AML and ALL cell lines treated with
various drug concentrations was determined by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay modified after Mosman [32], as previously
described [37]. Cells suspended in 100 μL cell culture
medium were plated per well in 96-well plates and incu-
bated in the presence of various drug concentrations for
96 h. Then, 25 μL of MTT solution (2 mg/mL (w/v) in
PBS) were added per well, and the plates were incubated
at 37 °C for an additional 4 h. After this, the cells were
lysed using 100 μL of a buffer containing 20% (w/v) so-
dium dodecylsulfate in 50% (v/v) N,N-dimethylforma-
mide with the pH adjusted to 4.7 at 37 °C for 4 h.
Absorbance was determined at 570 nm for each well
using a 96-well multiscanner (Tecan Spark, Tecan, Crail-
sheim, Germany). After subtracting of the background
absorption, the results are expressed as percentage via-
bility relative to control cultures which received no drug.
Drug concentrations that inhibited cell viability by 50%
(IC50) were determined using CalcuSyn (Biosoft, Cam-
bridge, UK) or GraphPad Prism (San Diego, CA, USA).
For AML blasts viability assays were performed using
the CellTiter-Glo (Promega, Walldorf, Germany) assay
according to the manufacturer’s protocol. Briefly, cells
were seeded at 5000 cells per well in 96-well plates and
treated for 96 h. Luminescence was measured on a
Tecan Spark (Tecan). IC50 values were calculated using
GraphPad Prism.
Caspase 3/7 assay
To determine Caspase 3/7 activity in THP-1 SAMHD1
KO and CTRL cells the Caspase-Glo 3/7 assay (Pro-
mega, Walldorf, Germany) was used according to the
manufacturer’s protocol. Briefly, cells were seeded at
5000 cells per well in white 96-well plates, treated with
different concentrations of CNDAC and incubated for
24, 48 and 72 h at 37 °C in a humidified 5% CO2 incuba-
tor. After incubation an equal volume of Caspase-Glo 3/
7 reagent was added, mixed for 30 min and lumines-
cence was measured on a Tecan Spark (Tecan).
Determination of population doubling time (PDT)
To generate a growth curve, cells were seeded at 2000
cells per well in a white 96-well plate in 100 μl culture
medium and incubated for 0, 1, 2, 3, 4 and 7 days at
37 °C in a humidified 5% CO2 incubator. Cell viability
was detected using the CellTiter-Glo assay (Promega)
according to the manufacturer’s protocol. Growth curves
were created and the population doubling times calcu-
lated using the following formula:
PDT ¼ cultivation period h½   log10 2ð Þ
log10 final cell countð Þ− log10 starting cell countð Þ
Western blot analysis
Whole-cell lysates were prepared by using Triton-X
sample buffer containing protease inhibitor cocktail
from Roche (Grenzach-Wyhlen, Germany). The protein
concentration was assessed by using the DC Protein
assay reagent obtained from Bio-Rad Laboratories. Equal
protein loads were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and proteins were
transferred to nitrocellulose membranes (Thermo Scien-
tific, Dreieich, Germany). The following primary anti-
bodies were used at the indicated dilutions: SAMHD1
(Proteintech, St. Leon-Roth, Germamy, 12,586–1-AP, 1:
1000), β-actin (BioVision, Milpitas, CA, US, 3598R-100,
1:5000), pSAMHD1 (Cell Signaling, Frankfurt am Main,
Germany, 89930S, 1:1000), GAPDH (Trevigen via Bio-
Techne, Wiesbaden, Germany, 2275-PC-10C, 1:5000),
DCK (abcam, Berlin, Germany, ab96599, 1:4000), DGK
(Santa Cruz Biotechnology, Heidelberg, Germany, sc-
398,093, 1:100), PARP (Cell Signaling, 9542S, 1:1000),
H2AX (Cell Signaling, 2595S, 1:1000), γH2AX (Cell Sig-
naling, 9718S, 1:1000), Chk2 (Cell Signaling, 2662S, 1:
1000), pChk2 (Cell Signaling, 2661S, 1:1000), TIF-1β
(Cell Signaling, 4124S, 1:1000), pTIF-1β (Cell Signaling,
4127S, 1:1000). Visualisation and quantification were
performed using IRDye-labeled secondary antibodies
(LI-COR Biotechnology, Bad Homburg, Germany,
IRDye®800CW Goat anti-Rabbit, 926–32,211 and
IRDye®800CW Goat anti-Mouse IgG, 926–32,210) ac-
cording to the manufacturer’s instructions. Band volume
analysis was conducted by Odyssey LICOR.
Flow cytometry
The intracellular SAMHD1 staining of AML blasts was
performed as previously described [3] with SAMHD1-
antibody from Proteintech (12586–1-AP, 1:100). Staining
for surface markers (CD33, CD34, CD45) for AML blasts
was applied before fixation with the following
fluorochrome-conjugated antibodies: CD33-PE and
CD34-FITC, both from Miltenyi Biotech (130–111-019,
130–113-178) and CD45-V450 from BD Pharmingen
(Heidelberg, Germany, 642,275), all diluted 1:5 per 1 ×
107 cells, and goat anti-rabbit Alexa-Fluor-660 from
Invitrogen, Life technologies (1:200, A-21073) as second-
ary antibody for SAMHD1 staining. Samples were ana-
lysed by using a FACSVerse flow cytometer from BD
Biosciences (Heidelberg, Germany) and the FlowJo soft-
ware (FlowJo LLC, Ashland, OR, US). To determine the
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mean fluorescence intensity (MFI) for SAMHD1, the
geometric mean for the isotype control was subtracted
from the geometric mean for SAMHD1.
SAMHD1 promoter methylation
The SAMHD1 promoter contains five HpaII sites sur-
rounding the transcription start site [7]. To measure
methylation of the SAMHD1 promoter genomic DNA
was treated with the methylation-sensitive HpaII endo-
nuclease as described previously [7, 36]. Methylation of
the HpaII sites in the SAMHD1 promoter prevents di-
gestion by HpaII and the intact sequence serves then as
a template for PCR amplification using SAMHD1
promoter-specific primers that flank the HpaII sites:
PM3.fwd: TTCCGCCTCATTCGTCCTTG and PM3.rev:
GGTTCTCGGGCTGTCATCG were used as SAMHD1
promoter-specific primers. A single PCR product (993-
bp) corresponding to the SAMHD1 promoter sequence
was obtained from untreated genomic DNA and treated
DNA from cells with methylated but not from cells with
unmethylated SAMHD1 promoter. To serve as input
control, a 0.25-kb fragment of the GAPDH gene lacking
HpaII sites was PCR-amplified using the same template
DNA.
Manipulation of cellular SAMHD1 levels using siRNA or
Vpx-VLPs
For siRNA-mediated silencing, AML cells (1 × 106) were
transfected with 2.5 μM ON-TARGET plus human
SAMHD1 siRNA SMART-pool obtained from Dharma-
con (Munich, Germany, L-013950-01-0050) in resuspen-
sion electroporation buffer R (Invitrogen, Dreieich,
Germany) using the Neon transfection system (Invitro-
gen) according to the manufacturer’s recommendation.
Additionally, ON-TARGET plus Non-targeting Control
Pool obtained from Dharmacon (D-001810-10-50) was
transfected in parallel. The electroporation was per-
formed with one 20 msec pulse of 1700 V and analysed
48 h after transfection by western blotting and a cell via-
bility assay.
For Vpx virus-like particle (VLP)-mediated SAMHD1
degradation, cells were spinoculated with VSV-G pseu-
dotyped virus-like particles carrying either Vpx or Vpr
as control from SIVmac251. VLPs carrying Vpx or Vpr
were produced by co-transfection of 293 T cells with
pSIV3 + gag pol expression plasmids and a plasmid en-
coding VSV-G as previously described [36, 41]. For via-
bility assays cells were preincubated with VLPs for 24 h
before the studied compounds were added.
LC-MS/MS analysis
AML or ALL cells were seeded at 2.5 × 105 cells per well
in 24 well plates, treated with 10 μM CNDAC and incu-
bated at 37 °C in a humidified 5% CO2 incubator for 6 h.
Subsequently, cells were washed twice in 1ml PBS, pel-
leted and stored at − 80 °C until measurement. The con-
centrations of canonical dNTPs and CNDAC-
triphosphate in the samples were analysed by liquid
chromatography-electrospray ionization-tandem mass
spectrometry, as previously described for canonical
dNTPs [43]. Briefly, the analytes were extracted by pro-
tein precipitation with methanol. An anion-exchange
HPLC column (BioBasic AX, 150 × 2.1 mm, 5 μM,
Thermo Scientific) was used for the chromatographic
separation and a 5500 QTrap (Sciex, Darmstadt,
Germany) was used as analyser, operating as triple quad-
rupole in positive multiple reaction monitoring (MRM)





as internal standard (IS). The precursor-to-product ion
transition used as quantifier was m/z 493.1→ 112.1 for
CNDAC-TP. Owing to the lack of commercially avail-
able standards for CNDAC-TP, relative quantification
was performed by comparing the peak area ratios (ana-
lyte/IS) of the differently treated samples.
Protein expression and purification
N-terminal 6 × His-tagged SAMHD1 (residues 113 to
626, H206R D207N) was expressed in BL21 (DE3)
Escherichia coli grown in Terrific Broth medium at 200
rpm, 18 °C for 16 h. Cells were re-suspended in buffer
and passed through a microfluidizer. Cleared lysates
were purified using nickel-nitrilotriacetic acid (Ni-NTA)
affinity and size-exclusion chromatography. Proteins
were stored in a buffer containing 50mM Tris-HCl, pH
8, 150 mM NaCl, 0.5 mM TCEP, 5 mM MgCl2, and 10%
glycerol.
Crystallization and data collection
Purified SAMHD1 protein in buffer (50 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 5 mM MgCl2, and 0.5 mM TCEP)
was mixed with 1 mM GTP, 0.1 mM dATP, and 10mM
CNDAC. All crystals were grown at 25 °C using the
microbatch under-oil method by mixing 1 μL of protein
(3 mg/mL) with 1 μL of crystallization buffer (100 mM
succinate–phosphate–glycine (SPG) buffer, pH 7.4, 25%
PEG 1500; Qiagen). Crystals were improved by streak
seeding. Crystals were cryoprotected in paratone oil and
frozen in liquid nitrogen. Diffraction data were collected
at Advanced Photon Source beamline 24-ID-E. The data
statistics are summarized in Table 1.
Structure determination and refinement
Using the previously published SAMHD1 tetramer
structure (PDB ID code 4BZB), with the bound nucleo-
tides removed, as the search model, the structure was
solved by molecular replacement using PHASER [29, 45,
46]. The model was refined with iterative rounds of
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restrained refinement using Refmac5 [33], followed by
rebuilding the model to the 2Fo-Fc and the Fo-Fc maps
using Coot [8]. Refinement statistics are summarised in
Suppl. Table 5. Coordinates and structure factors have
been deposited in the Protein Data Bank, with accession
codes listed in Suppl. Table 5.
Enzymatic assay
In vitro SAMHD1 activity was measured as described
[42]. Briefly, 1 μM his-tagged human SAMHD1 and
1.5 μM PPase from E.coli were incubated at room
temperature in 20 μL reaction buffer (50 mM Tris, 150
mM NaCl, 1.25 mM MgCl2, 0.5 mM TCEP, 0.05% Brij-
35) and different concentrations of GTP, dGTP and
CNDAC-TP in a clear 384-well plate (Corning, 3700,
New York, USA). Reactions were stopped by addition of
20 μL EDTA (20 mM in water). Subsequently, 10 μL
malachite green reagent (Sigma-Aldrich, MAK307, Mis-
souri, USA) were added. Absorbance was recorded at
620 nm after incubating the samples for 60 min at room
temperature. For normalization, background subtraction
of controls containing the same substrate and PPase
concentrations but no SAMHD1 was performed.
Statistics
Statistical data analysis was performed using GraphPad
Prism. Pearson’s correlation coefficient was used to com-
pute correlations between variables, using a t-test to as-
sess significance of the correlation. Group comparisons
were performed using Student’s t-test.
Results
SAMHD1 levels correlate with leukaemia cell sensitivity to
CNDAC
Initially, we characterised a panel of 13 human AML cell
lines for the levels of SAMHD1 and deoxycytidine kinase
(DCK) (Fig. 1A). DCK phosphorylates and activates cyti-
dine analogues in a rate-limiting step [15, 28, 48] and
may, hence, determine cell sensitivity to a nucleoside
analogue like CNDAC anticipated to be a SAMHD1 in-
hibitor [14]. We detected varying SAMHD1 and DCK
levels (Fig. 1A, Suppl. Figure 1), varying CNDAC con-
centrations that reduced cell viability by 50% (IC50) (Fig.
1B, Suppl. Figure 2, Suppl. Table 1), and varying CNDA
C-TP levels (Fig. 1C) across the investigated cell lines.
However, the CNDAC IC50s did not correlate with the
cellular levels of DCK (Fig. 1D), indicating that DCK is
not a critical determinant of CNDAC activity in our cell
line panel.
In contrast, the CNDAC IC50s correlated with the cel-
lular SAMHD1 levels (Fig. 1E), suggesting that
SAMHD1 may cleave and inactivate CNDAC-TP, al-
though CNDAC had been proposed to be a SAMHD1
inhibitor [14]. Also, there was no correlation between
cellular CNDAC-TP and DCK levels (Fig. 1F), but an in-
verse correlation of the CNDAC-TP levels with
SAMHD1 (Fig. 1G). This further supports the notion
that SAMHD1 but not DCK critically determines CNDA
C phosphorylation and activity. Notably, SAMHD1 pro-
moter methylation (Fig. 1H) did not always indicate cel-
lular SAMHD1 levels (Fig. 1A), showing that multiple
mechanisms are involved in regulating the cellular abun-
dance of this protein.
The CNDAC IC50s also correlated with the cellular
SAMHD1 levels in acute lymphoblastic leukaemia (ALL)
cells (Fig. 1I, Suppl. Table 2). In agreement with previ-
ous findings [39], T-cell ALL (T-ALL) cells were charac-
terised by lower SAMHD1 levels than B-ALL cells (Fig.
1J). This was reflected by higher CNDAC sensitivity (Fig.
1K) and higher CNDAC-TP levels (Fig. 1L) in T-ALL
cells than in B-ALL cells. Taken together, these findings
suggest that CNDAC is a SAMHD1 substrate and that
SAMHD1 but not DCK critically determines CNDAC
phosphorylation and activity in AML and ALL cells.
SAMHD1 suppression sensitises leukaemia cells to CNDAC
Functional studies further confirmed the impact of
SAMHD1 on CNDAC activity. THP-1 AML cells, in
which the SAMHD1 gene was disrupted using CRISPR/
Cas9 (THP-1 KO cells), displayed increased CNDAC
sensitivity (Fig. 2A) and CNDAC-TP levels (Fig. 2B) rela-
tive to control cells. Moreover, THP-1 KO cells showed
enhanced DNA damage, as indicated by γH2AX levels,
CHK2 phosphorylation, and TIF1β phosphorylation (Fig.
2C), and apoptosis, as indicated by PARP cleavage (Fig.
2C) and caspase 3/7 activity (Fig. 2D, Suppl. Table 3), in
response to CNDAC. This is in line with the anticipated
mechanism of action of CNDAC, i.e. CNDAC-TP in-
corporation into DNA resulting in strand breaks and
apoptosis [1, 2, 12, 24–27].
Further, SAMHD1 depletion using siRNA (Fig. 2E,
Suppl. Figure 3) and virus-like particles (VLPs) carrying
the lentiviral VPX protein (VPX-VLPs) [41] (Fig. 2F) in-
creased the CNDAC sensitivity of AML cell lines. VPX-
VLP-mediated SAMHD1 depletion was also associated
with elevated CNDAC-TP levels (Fig. 2G). These find-
ings further support a critical role of SAMHD1 in deter-
mining CNDAC sensitivity of AML cells.
SAMHD1 determines sensitivity of primary AML cells
CNDAC sensitivity also correlated with the cellular
SAMHD1 levels in primary leukaemic blasts derived
from the bone marrow of 24 therapy-naïve AML pa-
tients (Fig. 3A, Suppl. Figure 4, Suppl. Table 4). More-
over, primary leukaemic blasts were sensitised by VPX-
VLPs to CNDAC (Fig. 3B, Fig. 3C, Suppl. Figure 5) and
VPX-VLP-mediated SAMHD1 depletion resulted in in-
creased CNDAC-TP levels in AML blasts (Fig. 3D, Fig.
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Fig. 1 SAMHD1 (but not DCK) levels determine sensitivity to CNDAC and inversely correlate with CNDAC-triphosphate (CNDAC-TP) in leukaemia
cell lines. (A) Representative Western blots of SAMHD1, phosphorylated SAMHD1 (pSAMHD1), and DCK in 13 AML cell lines. GAPDH served as
loading control. Uncropped Western blots are presented in Supplementary Figure 1. (B) CNDAC concentrations that reduce the viability of AML
cell lines by 50% (IC50). Horizontal lines and error bars represent means ± SD of three independent experiments. (C) CNDAC triphosphate
(CNDAC-TP) levels determined by LC–MS/MS. Horizontal lines and error bars show means ± SD of three independent experiments. (D, E)
Correlation of the CNDAC IC50 values with cellular DCK (D) or SAMHD1 (E) protein levels, quantified using near-infrared Western blot images to
determine the ratio DCK/ GAPDH or SAMHD1/GAPDH. Closed circles and error bars represent means ± SD of three independent experiments.
Linear regression analyses were performed using GraphPad Prism. (F, G) Correlation of CNDAC-TP levels with cellular DCK (F) or SAMHD1 (G)
protein levels in AML cell lines, quantified using near-infrared Western blot images to determine the ratio DCK/GAPDH or SAMHD1/GAPDH.
Closed circles and error bars represent means ± SD of three independent experiments. Linear regression analyses were performed using
GraphPad Prism. (H) Analysis of SAMHD1 promoter methylation in AML cell lines through amplification of a single PCR product (993-bp)
corresponding to the promoter sequence after HpaII digestion. A 0.25-kb fragment of the GAPDH gene lacking HpaII sites was PCR-amplified
using the same template DNA served as loading control. THP-1 served as control cell for an unmethylated SAMHD1 promotor, while JURKAT
served as control cell for a methylated promotor. (I) Correlation of CNDAC IC50 values in 26 ALL cell lines (11 T-ALL, 15 B-ALL) with SAMHD1
protein levels, quantified using near-infrared Western blot images to determine the ratio SAMHD1/ GAPDH relative to the positive control THP-1.
Closed circles and error bars represent means ± SD of three independent experiments. Linear regression analyses were performed using
GraphPad Prism. (J-L) Comparison of SAMHD1 protein levels (J), CNDAC IC50 values (K) and CNDAC-TP levels determined by LC-MS/MS (L) in T-
ALL and B-ALL cells. Each point represents the mean of three independent experiments. One-tailed Student’s t-tests were used to compare
means in T-ALL and B-ALL cells (represented as horizontal lines ± SEM)
Rothenburger et al. Journal of Experimental & Clinical Cancer Research          (2021) 40:317 Page 7 of 19
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3E). This shows that SAMHD1 also determines CNDAC
sensitivity in clinical AML samples.
SAMHD1 hydrolyses CNDAC triphosphate (CNDAC-TP)
Next, we studied the interaction of CNDAC-TP and
SAMHD1 in an enzymatic assay. SAMHD1 forms a
homotetramer complex that cleaves nucleoside triphos-
phate (Suppl. Figure 6). Tetramer formation depends on
nucleoside triphosphate binding to the allosteric
SAMHD1 sites 1 (A1) and A2. A1 is activated by guano-
sine triphosphate (GTP) or desoxy-guanosine triphos-
phate (dGTP) binding. A2 can be activated by any
canonical deoxy-nucleoside triphospate (dNTP) and
some triphosphorylated deoxyribose-based nucleoside
analogues such as cladribine-TP and decitabine-TP
(Suppl. Figure 6) [14, 16, 17, 21, 36]. Arabinose-based
nucleoside analogue triphosphates (e.g. cytarabine-TP,
fludarabine-TP, or arabinosylguanine-TP (AraG-TP, the
active metabolite of nelarabine), and the triphosphory-
lated 2′-deoxy-2′-fluororibose-based nucleoside
analogue clofarabine depend on the activation of A2 by
canonical nucleotides [14, 21, 36].
Results from the enzymatic assay confirmed that
SAMHD1 hydrolyses CNDAC-TP only in the presence
of dGTP (Fig. 4A). This indicates that CNDAC-TP is a
SAMHD1 substrate but not able to activate the enzyme
by binding to A1 and A2.
Crystal structure of CNDAC-TP bound to SAMHD1
To investigate the interaction of CNDAC-TP and
SAMHD1 further, we crystallised the catalytically in-
active HD domain (residues 113–626; H206R, D207N)
of SAMHD1 in the presence of GTP, dATP, and excess
CNDAC-TP as previously described [21] and collected
diffraction data to 2.8 Å. SAMHD1 crystallised as a
tetramer with GTP and dATP occupying A1 and A2, re-
spectively, and CNDAC-TP bound to the catalytic site
(Fig. 4B, Suppl. Table 5).
Previous studies investigating the binding of tripho-
sphorylated nucleoside analogues to SAMHD1 showed
that modifications at the 2’ribose (R) position are major
determinants of interaction with the catalytic SAMHD1
site [21]. Analogues with 2’R modifications abrogate bind-
ing to SAMHD1, while 2′S stereoisomers are more per-
missive. Furthermore, the catalytic site tolerates larger 2′S
modifications, whereas analogue binding at the A2 site is
either impaired or fully blocked by 2′S fluorination or hy-
droxylation of the sugar ring, respectively [21].
Consistent with these observations, the CNDAC-TP-
bound SAMHD1 adopts the same conformation as the
canonical nucleotide-bound form (overall RMSD: 0.30 Å
vs PDB ID 4BZB). The ribose 2′S nitrile modification of
CNDAC-TP (Fig. 4C) protrudes outward from the cata-
lytic pocket without affecting canonical nucleotide con-
tacts with active site residues. CNDAC-TP is therefore
easily accommodated in the catalytic site to serve as a
substrate for SAMHD1 triphosphohydrolase activity.
However, the large nitrile group of CNDAC-TP prevents
binding to the more restrictive A2 site. Thus, CNDAC
alone is insufficient for SAMHD1 activation.
Impact of CNDAC on cellular levels of physiological
nucleoside triphosphates and the activity of SAMHD1
substrates
The finding that CNDAC-TP is itself a substrate of
SAMHD1 does not exclude the possibility that it also ex-
erts inhibitory effects on SAMHD1, as previously sug-
gested [14]. Hence, we investigated the effects of CNDA
C on the levels of physiological desoxynucleoside tri-
phosphates (dNTPs) and the activity of cytarabine, the
triphosphate of which is known to be a SAMHD1 sub-
strate [41].
CNDAC did in contrast to VPX-VLPs, which served as
a positive control for suppressing SAMHD1 activity, not
increase the levels of physiological dNTPs (Fig. 4D).
Moreover, CNDAC did not increase the activity of cytar-
abine (Fig. 4E). Thus, these findings do not suggest a
(See figure on previous page.)
Fig. 2 SAMHD1 suppression sensitises AML cells to CNDAC. (A) CNDAC dose-response curves in THP-1 knockout (THP-1 KO) cells, in which the
THP-1 gene was disrupted using CRISPR–Cas9, or control cells (THP-1 CTRL). Values represent means ± SD of three independent experiments.
Concentrations that reduce cell viability by 50% (IC50s) ± SD are provided. (B) Representative LC-MS/MS analysis of CNDAC triphosphate (CNDAC-
TP) levels in THP-1 KO and THP-1 CTRL cells. (C) Representative Western blots indicating levels of proteins involved in DNA damage response in
THP-1 KO and THP-1 CTRL cells after treatment with increasing CNDAC concentrations (0, 3.2, 16, 80, 400, and 2000 nM) for 72 h. (D) Caspase 3/7
activity in THP-1 KO and THP-1 CTRL cells after treatment with increasing CNDAC concentrations (0.015, 0.9375 and 60 μM) for 24, 48, and 72 h,
relative to untreated controls. Mean ± SD is provided for one representative experiment out of three using three technical replicates. p-values
were determined by two-tailed Student’s t-tests (*p < 0.05; **p < 0.01; ***p < 0.001). (E) CNDAC IC50 values in AML cells after transfection with
SAMHD1-siRNAs (siSAMHD1) or non-targeting control siRNAs (siCTRL). Values represent the means ± SD of three technical replicates of one
representative experiment out of three. p-values were determined by two-tailed Student’s t-tests (*p < 0.05; **p < 0.01; ***p < 0.001). (F) CNDAC
dose-response curves in AML cell lines treated with CNDAC in the absence or presence of VPX virus-like particles (VPX-VLPs, cause SAMHD1
depletion), or VPR virus-like particles (VPR-VLPs, negative control). Values represent the means ± SD of three technical replicates of one
representative experiment out of three. (G) Representative Western Blots and LC-MS/MS analyses of CNDAC-TP levels in AML cells treated with
VPX-VLPs or control VPR-VLPs
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pharmacologically relevant activity of CNDAC as
SAMHD1 inhibitor in AML cells.
Clonal heterogeneity in SAMHD1 levels drives intrinsic
AML cell resistance to CNDAC
When we established twelve single cell-derived clones of
the AML cell line MV4–11 by limiting dilution (Fig. 5A),
we determined an up to 332-fold difference in CNDAC
sensitivity (CNDAC IC50 clone 1: 0.065 μM, CNDAC IC50
clone 11: 21.6 μM; Fig. 5B, Suppl. Figure 7). Moreover, the
MV4–11 clones displayed substantial discrepancies in the
cellular SAMHD1 levels (Fig. 5C), but no changes in
SAMHD1 promoter methylation (Fig. 5D).
There was a significant correlation between SAMHD1
protein levels (but not the DCK protein levels) and the
CNDAC IC50s (Fig. 5E), and siRNA-mediated SAMHD1
depletion resulted in increased CNDAC (but not dauno-
rubicin) sensitivity in three selected clones displaying differ-
ing SAMHD1 levels (Fig. 5F, Suppl. Figure 8). The different
effects of SAMHD1 on CNDAC- and daunorubicin-
mediated toxicity suggest that SAMHD1 interferes with
CNDAC activity predominantly by cleaving CNDAC-TP
and not by generally augmenting DNA repair.
Differences in cellular SAMHD1 levels may affect cell
proliferation [10, 22, 23, 49], but there was no significant
correlation between the SAMHD1 (or DCK) levels of
the MV4–11 clones and their doubling times (Fig. 5G).
Taken together, these findings confirm that the re-
sponse to CNDAC is primarily driven by the SAMHD1
levels in CNDAC-naïve AML cells.
Fig. 3 SAMHD1 determines CNDAC sensitivity of primary AML cells. (A) Correlation of SAMHD1 protein levels and CNDAC concentrations that
reduce cell viability by 50% (IC50s) in bone-marrow-derived leukaemic blasts derived from 24 therapy-naïve AML patients. Cells were co-
immunostained for CD33, CD34, CD45 (surface markers) and intracellular SAMHD1 and the mean fluorescence intensity (MFI) was analysed by
flow cytometry. ATP assays were performed in three technical replicates to determine the CNDAC IC50 values. Linear regression analyses were
performed using GraphPad Prism. (B) CNDAC IC50 values in bone-marrow-derived leukaemic blasts derived from six therapy-naïve AML patients
either treated with VPX virus-like particles (VPX-VLPs, cause SAMHD1 depletion), VPR virus-like particles (VPR-VLPs, negative control), or left
untreated. Horizontal lines and error bars indicate means ± SD of three technical replicates. p-values were determined by two-tailed Student’s t-
tests (*p < 0.05; **p < 0.01; ***p < 0.001). (C) CNDAC dose-response curves in primary AML cells of one exemplary patient (Patient E) treated with
VPX-VLPs, VPR-VLPs or left untreated. IC50 values represent means ± SD of three technical replicates. (D) Representative Western blots indicating
SAMHD1 levels in primary AML cells derived from Patient E in response to treatment with VPX-VLPs. (E) CNDAC-triphosphate (CNDAC-TP) levels
as determined by LC-MS/MS in primary AML cells derived from Patient E in response to treatment with VPX-VLPs
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Acquired resistance to CNDAC is associated with
decreased DCK levels
To investigate the role of SAMHD1 in acquired CNDAC
resistance, we established twelve CNDAC-resistant sub-
lines of each of the AML cell lines HL-60 and PL-21,
which are characterised by low SAMHD1 levels (Fig.
1A) and high CNDAC sensitivity (Fig. 1B). Interestingly,
none of the 24 resulting CNDAC-resistant sublines dis-
played increased SAMHD1 levels but all showed re-
duced, virtually non-detectable DCK levels (Fig. 6A).
Among twelve single cell-derived clones of HL-60 and
PL-21, none displayed similarly low DCK levels (Fig.
6A).
Then, we determined resistance profiles in the
CNDAC-resistant HL-60 and PL-21 sublines and the
clonal HL-60 and PL-21 sublines to a set of cyto-
toxic (CNDAC, sapacitabine, cytarabine, clofarabine,
cladribine, fludarabine, gemcitabine, decitabine, aza-
cytidine, 6-thioguanine, daunorubicin) and targeted
(venetoclax, vismodegib, olaparib, ganetespib, vola-
sertib, gedatolisib, molibresib) drugs (Fig. 6B, Suppl.
Table 6).
Fig. 4 CNDAC triphosphate (CNDAC-TP) is a SAMHD1 substrate. (A) Normalised results from a colorimetric SAMHD1 activity assay carried out in
presence of different combinations of GTP, dGTP and CNDAC-TP. Horizontal lines and error bars represent means ± SD from three independent
experiments. (B) Surface view of SAMHD1 tetramer with each subunit in a different colour. CNDAC-TP in a catalytic pocket is shown in magenta
sticks. (B, inset) CNDAC-TP bound to the SAMHD1 catalytic pocket. Black asterisks indicate the site of nitrile modification. The SAMHD1 backbone
is shown as ribbons with side chains shown as sticks. A magnesium ion is shown as a green sphere and coordinated waters are shown as red
spheres. Portions of the structure are omitted for clarity. (C) Chemical structure of CNDAC with 2′S nitrile modification highlighted (left). 2Fo-Fc
electron density (σ = 1.0) for CNDAC-TP co-crystallized in the catalytic pocket of SAMHD1 (right). Black asterisks indicate site of nitrile modification.
(D) Concentrations of physiological dNTPs in THP-1 cells determined by LC-MS/MS after pre-treatment with VPX virus-like particles (VPX-VLPs,
cause SAMHD1 depletion), VPR virus-like particles (VPR-VLPs, negative control), and with or without cytarabine (Ara-C) or CNDACs. Bars and error
bars represent means ± SD from three independent measurements. The Lower Limit of Quantification (LLOQ) for dGTP was 0.2 ng/Pellet, so
values below the LLOQ were set to 0.2 ng/Pellet (CNDAC and CNDAC + VPR). p-values were determined by two-tailed Student’s t-tests (*p < 0.05;
**p < 0.01; ***p < 0.001). (E) AraC IC50s in THP-1 cells in the presence of different CNDAC concentrations (0, 0.375, 0.75, 1.5 μM). Horizontal lines
and error bars represent means ± SD of three technical replicates of one representative experiment out of three. p-values were determined by
two-tailed Student’s t-tests (*p < 0.05; **p < 0.01; ***p < 0.001)
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In addition to resistance to CNDAC and its prodrug
sapacitabine, all CNDAC-adapted sublines also consist-
ently displayed a markedly reduced sensitivity to the nu-
cleoside analogues clofarabine, cladribine, fludarabine,
gemcitabine, and decitabine, whose activation critically
depends on monophosphorylation by DCK (Fig. 6B,
Suppl. Table 6). In contrast, there was no cross-
resistance to the nucleoside analogues azacytidine and 6-
thioguanine that are no DCK substrates and to the
anthracycline daunorubicin. This suggests that the re-
duced DCK expression is the predominant acquired re-
sistance mechanism in our panel of CNDAC-adapted
AML cell lines.
This notion was also confirmed by the general lack of
cross-resistance to targeted drugs with a range of differ-
ent targets, including the smoothend receptor (vismode-
gib), PARP1 (olaparib), HSP90 (ganetespib), PLK1
(volasertib), and PI3K/mTOR (gedatolisib). There was
some level of resistance to the BET inhibitor molibresib
among the CNDAC-adapted sublines (Fig. 6B, Suppl.
Table 6). However, some level of resistance to these
drugs was also detected among the clonal HL-60 and
PL-21 sublines (Fig. 6B, Suppl. Table 6), which may sug-
gest that this molibresib resistance may rather be the
consequence of clonal selection processes during resist-
ance formation and not part of the acquired CNDAC re-
sistance mechanisms.
The Bcl-2 inhibitor venetoclax was the only targeted
drug against which the CNDAC-adapted sublines dis-
played an increased level of resistance that was not de-
tectable in the clonal sublines (Fig. 6B, Suppl. Table 6).
This may indicate a generally increased resistance to
apoptosis in the CNDAC-adapted sublines (Fig. 6B,
Suppl. Table 6), which may reflect that apoptosis induc-
tion is anticipated to be part of the anti-cancer mechan-
ism of action of CNDAC [27].
Taken together, our findings suggest that DCK down-
regulation is the major acquired CNDAC resistance
mechanism in AML cells, potentially complemented by
a generally reduced potential to undergo apoptosis.
Role of SAMHD1 and DCK in CNDAC cross-resistance of
AML cell lines adapted to drugs from different classes
In contrast to the CNDAC-adapted AML cell lines in-
troduced here, which displayed reduced DCK expression
as main acquired resistance mechanism, AML cell lines
adapted to the SAMHD1 substrates cytarabine or decita-
bine were characterised by a combination of increased
SAMHD1 levels and decreased DCK levels [36, 41].
CNDAC-adapted AML sublines displayed pronounced
cross-resistance to nucleoside analogues that are acti-
vated by DCK but not to anti-leukaemia drugs with
other mechanisms of action (Fig. 6). In a reversed set-
ting, we next investigated CNDAC in a panel consisting
of the AML cell line HL-60 and its sublines adapted to
the nucleoside analogues cytarabine, Ara-G, azacytidine,
and fludarabine, the purine antagonist 6-
mercaptopurine, the Bcl-2 inhibitor venetoclax, the
PARP inhibitor olaparib, and the polo-like kinase 1 in-
hibitor volasertib.
The nucleoside analogue-resistant HL-60 sublines dis-
played increased SAMHD1 and/ or decreased DCK
levels (Fig. 7A) and pronounced CNDAC resistance (Fig.
7B, Suppl. Figure 9), while little or no CNDAC resist-
ance was detected in the remaining sublines (Fig. 7A,
Fig. 7B, Suppl. Figure 9). Moreover, cellular SAMHD1
levels directly and cellular DCK levels inversely corre-
lated with the CNDAC IC50s (Fig. 7C), indicating that
enhanced SAMHD1 levels and reduced DCK levels con-
tribute to cross-resistance to CNDAC. VPX-VLP-
mediated SAMHD1 depletion sensitised nucleoside
analogue-adapted HL-60 sublines to CNDAC to various
extents (Fig. 7D), which probably reflects the relative im-
portance of SAMHD1 and DCK levels for CNDAC re-
sistance in these cell lines.
Next, we used cytarabine-adapted MV4–11 and MOLM-
13 sublines to further study the role of SAMHD1 and DCK
in cross-resistance of nucleoside analogue-adapted AML
cells to CNDAC (Fig. 7E). In both cell lines, VPX-VLP-
mediated SAMHD1 depletion resulted in reduced CNDAC
IC50s, which further decreased upon forced DCK expression.
(See figure on previous page.)
Fig. 5 Clonal heterogeneity in SAMHD1 levels drives intrinsic resistance to CNDAC but not population doubling time in MV4-11 cells. (A) Schematic
illustration of the establishment of MV4-11 single cell-derived clones by limiting dilution. (B) CNDAC concentrations that reduce viability of 12 single-
cell-derived MV4-11 clones by 50% (IC50). Values represent means ± SD of three independent experiments. (C) Representative Western blots of
SAMHD1, phosphorylated SAMHD1 (pSAMHD1), and DCK in single cellderived MV4-11 clones. GAPDH served as a loading control. (D) Analysis of
SAMHD1 promoter methylation in MV4-11 clones through amplification of a single PCR product (993-bp) corresponding to the promoter sequence
after HpaII digestion. (E) Correlation of the CNDAC IC50 values with cellular SAMHD1 or DCK protein levels, quantified using nearinfrared Western blot
images to determine the ratio SAMHD1/ GAPDH or DCK/ GAPDH. Closed circles and error bars represent means ± SD of three independent
experiments, each performed in three technical replicates. Linear regression analyses were performed using GraphPad Prism. (F) Western Blots and IC50
values for CNDAC and daunorubicin in MV4-11 clones 9, 11, and 12 after transfection with SAMHD1-siRNAs (siSAMHD1) or non-targeting control
siRNAs (siCTRL). Each symbol represents the mean ± SD of three technical replicates of one representative experiment out of three. P-values were
determined by two-tailed Student’s t-test (*p < 0.05; **p < 0.01; ***p < 0.001). (G) Population doubling time (PDT) in MV4-11 single cell-derived clones
and correlation of the PDT with cellular SAMHD1 or DCK protein levels. Closed circles and error bars represent means ± SD from the quantification of
three Western Blots. Linear regression analyses were performed using GraphPad Prism
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Similar findings were obtained with regard to the cytarabine
resistance in these two cell lines (Fig. 7E). This confirms that,
in principle, cellular SAMHD1 and DCK levels are involved
in determining AML cell sensitivity to CNDAC (and cytara-
bine), although, as shown in this study, intrinsic and acquired
CNDAC resistance differ in AML cells in that intrinsic
CNDAC resistance is predominantly driven by high
SAMHD1 levels and acquired CNDAC resistance by a re-
duction in DCK.
Discussion
The findings of this study indicate that in AML cells
intrinsic CNDAC resistance is predominantly driven
by SAMHD1, whereas acquired CNDAC resistance is
primarily caused by reduced DCK levels. This differ-
ence is of potential clinical significance, because
SAMHD1 is a candidate biomarker for predicting
CNDAC sensitivity in therapy-naïve patients, while
DCK is a candidate biomarker for the early detection
of resistance formation.
SAMHD1 is known to interfere with the activity of a
range of anti-cancer nucleoside analogues as hydroxylase
that cleaves the activated nucleoside analogue triphos-
phates [[13, 21, 36, 39, 41]; Xagorias et al., 2021]. The
finding that SAMHD1 levels critically determine AML
(and ALL) cell sensitivity to CNDAC is nevertheless
somewhat unexpected, as CNDAC had originally been
suggested to be a SAMHD1 inhibitor [14].
However, data from a large range of cell line models
(including clonal AML sublines characterised by varying
SAMHD1 levels) and patient samples demonstrated that
high SAMHD1 levels are associated with reduced CNDA
C sensitivity and that CRISPR/Cas9-, siRNA-, and VPX-
VPL (virus-like particles carrying the lentiviral VPX pro-
tein)-mediated SAMHD1 depletion increase cellular
CNDAC-TP levels and sensitise AML cells to CNDAC.
In agreement, enzymatic assays and crystallisation stud-
ies showed that CNDAC-TP is cleaved by SAMHD1, but
can in contrast to some other nucleoside analogues [14,
16, 17, 21, 36] not activate SAMHD1 via binding to the
A2 site.
Moreover, the determination of physiological dNTPs
in the presence of CNDAC and combination experi-
ments with the SAMHD1 substrate cytarabine did not
provide evidence that CNDAC may function as pharma-
cological SAMHD1 inhibitor in leukaemia cells.
Although cellular SAMHD1 levels, but not those of
DCK that is critical for CNDAC phosphorylation and ac-
tivation [[15, 28]; Wu et al., 2021], predominantly deter-
mined CNDAC sensitivity in CNDAC-naïve cells, the
establishment of 24 CNDAC-resistant AML sublines
unanimously resulted in a loss of DCK but not in an in-
crease of SAMHD1. This differs from acquired resist-
ance mechanisms against the nucleoside analogues
cytarabine and decitabine that were found to include
both increased SAMHD1 levels and decreased DCK
levels [36, 41]. Two previously established CNDAC-
adapted cancer cell lines had been shown to display re-
duced DCK levels but a contribution of SAMHD1 had
not been investigated [34, 35].
CNDAC-adapted AML sublines consistently displayed
cross-resistance to other nucleoside analogues known to
be activated by DCK but no pronounced cross-
resistance to other drugs with various mechanisms of ac-
tion, further indicating that loss of DCK is the crucial re-
sistance mechanism in CNDAC-adapted cells. Moreover,
these data also show that drugs, which do not depend
on DCK for activation, remain viable treatment options
after resistance acquisition to CNDAC.
Similarly, among AML sublines adapted to a range of
different anti-cancer drugs, only nucleoside analogues
that displayed increased SAMHD1 and/ or decreased
DCK levels were less sensitive to CNDAC. Thus, ac-
quired resistance to a range of different anti-leukaemic
drugs is unlikely to affect the efficacy of CNDAC.
Cytarabine- and decitabine-adapted AML cell lines
are characterised by a combination of increased
SAMHD1 levels and/ or reduced DCK levels as demon-
strated previously [36, 41]. Although acquired CNDAC
(See figure on previous page.)
Fig. 6 Acquired resistance to CNDAC is associated with decreased DCK levels and accompanied by cross-resistance to DCK-dependent
nucleoside analogues. (A) Schematic illustrations of the establishment of CNDAC-resistant HL-60 and PL-21 cells by step-wise increasing drug
concentrations during cell culture and of the establishment of single cellderived clones by limiting dilution. Moreover, representative Western
blots indicating SAMHD1 and DCK levels in CNDAC-adapted HL-60 (HL-60rCNDACI-XII) and PL-21 (PL-21rCNDACI-XII) sublines and in single cell-
derived clonal sublines of these cell lines. GAPDH and β-Actin served as loading controls. (B) Resistance profiles of CNDAC-adapted HL-60 and PL-
21 sublines and single cell-derived clones of HL-60 and PL-21. Left spider webs show sensitivity to the cytotoxic drugs CNDAC, 6-Thioguanine (6-
TG), Clofarabine (CLOF), Cladribine (CLAD), Fludarabine (FLU), Gemcitabine (GEM), Decitabine (DAC), 5-Azacytidine (AZA), Daunorubicin (DAU),
Cytarabine (ARA-C), and Sapacitabine (SAP), while right spider webs display sensitivity to the targeted drugs Vismodegib (VISMO), Olaparib (OLA),
Ganetespib (GANE), Gedatolisib (GEDA), Volasertib (VOLA), Molibresib (MOLI), and Venetoclax (VENE). Values are depicted as fold changes in drug
concentrations that reduce cell viability by 50% (IC50s) between the respective parental AML cell line (shown in red) and the resistant cell lines or
clones. Points closer to the centre than red lines indicate higher sensitivity to drugs in CNDAC-resistant sublines or clonal sublines than in
parental cell lines, while points lying outside red lines indicate reduced sensitivity to the respective drug. IC50 fold changes are shown as means
from three independent experiments. Numerical values are provided in Supplementary Table 6
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resistance was mediated by decreased DCK levels, both
increased SAMHD1 levels and decreased DCK levels
contributed to cross-resistance of cytarabine-adapted
cells to CNDAC. In the future, it will be interesting to
investigate why acquired resistance mechanisms differ
between CNDAC-adapted cells on the one hand and
cytarabine- and decitabine-adapted cells on the other
hand.
Conclusion
Intrinsic AML cell response to CNDAC critically de-
pends on cellular SAMHD1 levels, whereas acquired
CNDAC resistance is predominantly mediated by re-
duced DCK levels. This adds to data demonstrating dif-
ferences between intrinsic and acquired resistance
mechanisms [31, 36, 40, 44]. These findings also indicate
that SAMHD1 is a candidate biomarker predicting
Fig. 7 SAMHD1 and DCK regulate CNDAC cross-resistance of AML cell lines adapted to drugs from different classes. (A) Representative Western blots
of SAMHD1, phosphorylated SAMHD1 (pSAMH1), DGK, and DCK in HL-60 sublines adapted to cytarabine (Ara-C), arabinosylguanine (Ara-G), 5-
azacytidine (AZA), fludarabine (FLU), 6-mercaptopurine (6-MP), venetoclax (VENE), olaparib (OLA), and volasertib (VOLA). GAPDH served as loading
control. (B) CNDAC concentrations that reduce cell viability by 50% (IC50s) in drug-adapted HL-60 sublines. Horizontal lines and error bars represent
means ± SD of three independent experiments, each performed in three technical replicates. p-values were determined by two-tailed Student’s t-tests
(*p < 0.05; **p < 0.01; ***p < 0.001). (C) Correlation of CNDAC IC50 values with cellular SAMHD1 or DCK protein levels, quantified using the near-
infrared Western blot image shown in (A) to determine the ratio SAMHD1/GAPDH or DCK/GAPDH. (D) CNDAC dose-response curves in drug-adapted
HL-60 sublines in the absence or presence of VPX virus-like particles (VPX-VLPs, cause SAMHD1 depletion) or VPR virus-like particles (VPR-VLPs, negative
control). Each symbol represents the mean ± SD of three technical replicates of one representative experiment out of three. Concentrations that
reduce AML cell viability by 50% (IC50s) ± SD and Western Blots showing SAMHD1 degradation by VPXVLPs are provided. (E) CNDAC or cytarabine
(Ara-C) dose-response curve in cytarabineadapted MV4-11 or MOLM-13 cells (characterised by loss of DCK expression) stably transduced with either
DCK (pWPI+DCK) or an empty vector (pWPI) in the absence or presence of VPX virus-like particles (VPX-VLPs), or VPR virus-like particles (VPR-VLPs). Each
symbol represents the mean ± SD of three technical replicates of one representative experiment out of three. IC50s (mean ± SD) and Western Blots
showing successful transduction with DCK and SAMHD1 degradation by VPX-VLPs are provided
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CNDAC response in the intrinsic resistance setting,
while DCK plays a potential role as biomarker indicating
therapy failure early in the acquired resistance setting.
Moreover, CNDAC-adapted cells displayed no or limited
cross-resistance to drugs whose activity is not influenced
by DCK or SAMHD1. Similarly, CNDAC was still effect-
ive in cells adapted to drugs that are not affected by
DCK or SAMHD1. These findings indicate treatment
options after therapy failure.
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